Galina V. Pazynina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Galina V. Pazynina has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alexey Nokel
Semiotik LLC, Moscow, Russia
2 shared publications - Nadezhda V. Shilova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, Moscow, Russia
2 shared publications - Nicolai Vladimirovich Bovin
Russian Academy of Sciences
2 shared publications - Alexander Chinarev
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, Moscow, Russia
1 shared publication - Alexander D. Lipatnikov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 16/10, Miklukho-Maklaya Street, Moscow 117997, Russia
1 shared publication - Alexandra Vladimirovna Semyanikhina
Federal State Budgetary Institution “National Medical Research Center of Oncology Named After N.N. Blokhin” of the Ministry of Health of the Russian Federation, 23, Kashirskoe Shosse, Moscow 115522, Russia
1 shared publication
Latest Publications
- 19 February 2026
- Published by Springer Nature in Archives of Virology
- Vol. 171 (3) , 75
Antibody-free detection of influenza viruses on a microarray to study their receptor specificity
- 19 February 2026
- Published by Springer Nature in Archives of Virology
- Vol. 171 (3) , 75
Antibody-free detection of influenza viruses on a microarray to study their receptor specificity
- Open Access
- 13 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 800
The Level of Antibodies to Tumor-Associated Glycans in Gastric Cancer Patients Is Lower than in Healthy Donors and Reduces with Age
A key function of naturally occurring antibodies is to control pathologically altered cells, such as those with aberrant glycosylation. Age-related diminution in the pool of B cells producing these immunoglobulins is linked to impaired anti-tumor immunity. In this study, the levels of antibodies against tumor-associated carbohydrate antigens (TACAs)—common in gastric cancer (GC) and other malignancies—were analyzed in 235 treatment-naïve GC patients (stages I–IV) and 76 healthy donors using a printed glycan array (PGA). We found that anti-glycan IgM levels, but not IgG, reduced with age in both patients and donors. Crucially, IgM levels against most glycans were significantly lower in the GC cohort compared with healthy donors, a trend that remained after age adjustment. Furthermore, an immunohistochemical analysis revealed that human anti-GalNAcα (Tn) antibodies—a well-characterized TACA in gastrointestinal cancers—bound to tumor cells and exhibited perinuclear and membrane staining in non-tumor surface cells within the same organ. These data support the hypothesis that gastric cancer patients have reduced levels of anti-glycan IgMs, which are responsible for the early recognition of transformed cells. This specific immunodeficiency may contribute to a permissive environment for tumor development.
- 13 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 800
Open AccessThe Level of Antibodies to Tumor-Associated Glycans in Gastric Cancer Patients Is Lower than in Healthy Donors and Reduces with Age
A key function of naturally occurring antibodies is to control pathologically altered cells, such as those with aberrant glycosylation. Age-related diminution in the pool of B cells producing these immunoglobulins is linked to impaired anti-tumor immunity. In this study, the levels of antibodies against tumor-associated carbohydrate antigens (TACAs)—common in gastric cancer (GC) and other malignancies—were analyzed in 235 treatment-naïve GC patients (stages I–IV) and 76 healthy donors using a printed glycan array (PGA). We found that anti-glycan IgM levels, but not IgG, reduced with age in both patients and donors. Crucially, IgM levels against most glycans were significantly lower in the GC cohort compared with healthy donors, a trend that remained after age adjustment. Furthermore, an immunohistochemical analysis revealed that human anti-GalNAcα (Tn) antibodies—a well-characterized TACA in gastrointestinal cancers—bound to tumor cells and exhibited perinuclear and membrane staining in non-tumor surface cells within the same organ. These data support the hypothesis that gastric cancer patients have reduced levels of anti-glycan IgMs, which are responsible for the early recognition of transformed cells. This specific immunodeficiency may contribute to a permissive environment for tumor development.